SCHEMBL5415192

SCHEMBL5415192

CC(=O)OCc1ccc(-c2c3c(=O)n(C)c(=O)n(CC(C)C)c3nn2Cc2c[nH]nc2-c2ccccc2)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.35
ALDH1A1 P00352 5/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
MAPT P10636 4/20 0.35
HPGD P15428 3/20 0.35
HSD17B10 Q99714 3/20 0.35
PDE1A P54750 2/20 0.34
PDE1B Q01064 2/20 0.34
PDE1C Q14123 2/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
MAPK1 P28482 2/20 0.33
HTT P42858 2/20 0.33
TSHR P16473 1/20 0.33
POLB P06746 2/20 0.33
KDM4E B2RXH2 2/20 0.33
CYP3A4 P08684 1/20 0.33
THRB P10828 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5410857 0.84 PDE1A (0.38) ALDH1A1MAPTPDE1APDE1BPDE1C
SCHEMBL5398277 0.83 LMNA (0.37) LMNAALDH1A1PDE1APDE1BPDE1C
SCHEMBL5400039 0.83 SLC16A1 (0.36) LMNAALDH1A1SMN1; SMN2MAPTPDE1A
SCHEMBL5417927 0.81 PDE1A (0.40) ALDH1A1MAPTPDE1APDE1BPDE1C
SCHEMBL5404004 0.80 MAPT (0.40) LMNAALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL5393473 0.80 KMT2A (0.40) LMNAALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL5407589 0.79 PDE1A (0.38) LMNAALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL5404313 0.79 PDE1A (0.36) LMNAALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL5397647 0.79 PDE1A (0.36) LMNAALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL5404321 0.79 PDE1A (0.36) LMNAALDH1A1SMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC LMNA 4673/4885ALDH1A1 903/4885SMN1; SMN2 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.